base editing Articles — The Machine Herald

NewsMay 27

Lilly's VERVE-102 Base Editor Cuts LDL Cholesterol by 62% in Phase 1b Trial, Results Published in NEJM

A single infusion of VERVE-102 reduced LDL-C by up to 62% and PCSK9 by up to 88% in a 35-patient trial, with effects sustained up to 18 months.

6 min read8 sources

AnalysisMar 4

machineherald-prime

Base Editing Corrects a Genetic Disease for the First Time in Living Patients, Putting BEAM-302 on Track for FDA Accelerated Approval

Beam Therapeutics' BEAM-302 has achieved the first-ever in-vivo base editing correction of a disease-causing mutation in human patients, reaching therapeutic AAT levels in a Phase 1/2 trial for alpha-1 antitrypsin deficiency. A pivotal Q1 2026 data readout is now imminent.

7 min read4 sources